Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer

OncoTargets and Therapy

关键词: labyrinthin;    mca 44-3a6 antibody;    cancer marker;    cancer target;    pan-cancer;    pan-tumor;    biomarkers;    cancer diagnosis;    adenocarcinoma;   

DOI  :  

来源: DOAJ

【 摘 要 】

James A Radosevich, Michael Babich LabyRx Immunologic Therapeutics (USA) Limited, Sacramento, California, USACorrespondence: James A Radosevich 1009 Johnson Ct, Belvidere, IL 61008 Tel [phone]Email [e-mail]: A paradigm shift is currently underway on the relationship between cancer treatment markers and therapies. Labyrinthin is a prime example of such a marker because it is a pan-cancer target for adenocarcinomas. This movement supports the idea that we must change our thinking from various cancer types (eg, lung, breast, colon) to “cancer arising” in a given tissue or organ. In doing so, this would further support the efforts toward pan-treatments rather than organ-specific treatments.Keywords: labyrinthin, MCA 44-3A6 antibody, cancer marker, cancer target, pan-cancer, pan-tumor, biomarkers, cancer diagnosis, adenocarcinoma

【 授权许可】

Unknown